The effects of a clinical care pathway for schizophrenia: A before and after study in 114 patients;Effekte eines klinischen Behandlungspfads "schizophrenie": Eine Prä-/Post-Untersuchung an 114 Patienten

Deutsches Arzteblatt International

Volumn 109, Issue 46, 2012, Pages 788-794

  Steinacher, Bruno ^a   Mausolff, Lieselotte ^b   Gusy, Burkhard ^c  

^a Vivantes Wenckebach Klinikum   (Germany)

^b Kliniken im Theodor Wenzel Werk   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG MONITORING; ELECTROCARDIOGRAM; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; NEUROIMAGING; ONSET AGE; PATIENT CARE; PROSPECTIVE STUDY; PSYCHOLOGICAL WELL BEING; SCHIZOPHRENIA; SELF EVALUATION; THERAPY EFFECT; CLINICAL PATHWAY; GERMANY; MIDDLE AGED; PREVALENCE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UTILIZATION; YOUNG ADULT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CRITICAL PATHWAYS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PSYCHOTHERAPY; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902773588     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0788     Document Type: Article

References (22)

1. Dick B, Sitter H, Blau E, Lind N, Wege-Heuser E, Kopp I: Behandlungspfade in Psychiatrie und Psychotherapie. Nervenarzt 2006; 77: 12-22.
2. Burgers JS, Grol R, Klazinga NS, Mäkelä M, Zaat J: Towards evidence- based clinical practice: an international survey of 18 clinical guideline programs. Int J Qual Health Care 2003; 15: 31-45.
3. Gaebel W, Schwarz M, Janssen B: Qualitätsmanagement in der Psychiatrie. In: Gaebel W, Müller-Spahn F (eds.): Diagnostik und Therapie psychischer Störungen. Stuttgart: Kohlhammer 2002; 1257-73.
4. Wobrock T, Schneider F, Falkai P: Leitlinienintentionen der DGPPN. Nervenarzt 2010; 81: 1041-8.
5. Weinmann S, Koesters M, Becker T: Effects of implementation of psychiatric guidelines on provider performance and patient out - come: systematic review. Acta Psychiatr Scand 2007; 115: 420-33.
6. Karbach U, Schubert I, Hagemeister J, Ernstmann N, Pfaff H, Höpp HW: Physicians' knowledge of and compliance with guidelines: An exploratory study in cardiovascular diseases. Dtsch Arztebl Int 2011; 108(5): 61-9.
7. Grimshaw JM, Thomas RE, MacLennan G, et al.: Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004; 8: 1-84.
8. Clade H: Fallbeispiel Schizophrenie: Hohe soziale Kosten. Dtsch Arztebl 2003; 100: 1598-9.
9. Janssen B, Weinmann S, Berger M, et al.: Leitlinienkonformität und Behandlungsergebnisse in der stationären Schizophreniebehandlung - ein Klinikvergleich. Nervenarzt 2005; 76: 315-26.
10. Miller AL, Crismon ML, Rush AJ, et al.: The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull 2004; 30: 627-47.
11. Weinmann S, Hoerger S, Erath M, Kilian R, Gaebel W, Becker T: Implementation of a schizophrenia practice guideline: clinical results. J Clin Psychiatry 2008; 29: 1299-306.
12. Godemann F, Blittersdorf K, Poschenrieder M, Klimitz H, Hauth I, Gutzmann H: Leilinienkonformität in der Behandlung schizophrener Patienten: Einführung eines IT-gestützten Behandlungspfades. Nervenarzt 2010; 81: 584-93.
13. Owen RR, Thrush CR, Kirchner JE, Fischer EP, Booth BM: Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose. Int J Qual Health Care 2000; 12: 475-82.
14. Lehman AF, Kreyenbuhl J, Buchanan RW, et al.: The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004; 30: 193-217.
15. Lehman AF, Steinwachs DM: Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1-10.
16. Overall JE, Gorham DR: BPRS Brief Psychiatric Rating Scale. In: Guy W, Bonato RR (eds.): ECDEU Assessment Battery Rev. Ed. Rockville 1976; 157-69.
17. Honigfeld G, Gillis RD, Klett CJ: NOSIE Nurses' Observation Scale for Inpatient Evaluation. In: Guy W, Bonato RR (eds.): ECDEU Assessment Battery Rev. Ed. Rockville 1976; 265-73.
18. Süllwold L, Herrlich J: Frankfurter Befindlichkeitsskala (FBS) für schizophren Erkrankte. Berlin: Springer 1987.
19. Baldessarini RJ, Tarazi FI: Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG (eds.): Goodman and Gilman's the pharmacologic basis of therapeutics. New York: McGraw-Hill 2001; 485-520.
20. Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2002; 64: 663-7.
21. Chuang WC, Crismon ML: Evaluation of a schizophrenia medication algorithm in a state hospital. Am J Health Syst Pharm 2003; 60: 1459-67.
22. Linden M, Schotte K: A randomized controlled clinical trial compar - ing "guideline exposed" and "guideline naive" physicians in respect to dosage selection and treatment outcome with Doxepin in depressive disorders. Pharmacopsychiatry 2007; 40: 77-81.